Dynamic Frailty Assessment Underscores Need for Ongoing Evaluation in Transplant-Ineligible Multiple Myeloma: With Hira Mian, MD, MSc, FRCPC

Headliner Embed

Embed code See more options

Share

Facebook X

Subscribe

Dr Mian discussed why frailty should be understood as a dynamic, evolving clinical state rather than a fixed baseline characteristic

Share

Facebook X

Subscribe

Next

ARROS-1 Data Show Zidesamtinib's Favorable Safety Profile, Spark Discussion to Clarify Its Role in ROS1+ NSCLC: With Stephen Liu, MD

Top episodes

DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology

by OncLive® On Air

FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC

by OncLive® On Air

Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1

by OncLive® On Air

•   Report this episode
•   Download audio
•   QRCode